Study to Measure the Efficacy and Safety of Abrocitinib (PF-04965842) in Subjects Aged 12 Years And Older, With Moderate to Severe Atopic Dermatitis

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, With Moderate to Severe Atopic Dermatitis (JADE Mono-2)

Category & Conditions:
Skin Diseases and Conditions
Medicine:
abrocitinib (PF-04965842)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B7451013
Open Plain Language Summary Result:Click here